| RARE.Qc member(s) |
Institution |
Project title |
Amount |
Length |
| Hugues Allard-Chamard; Marie A. Brunet |
Université de Sherbrooke |
Osteoclast-Related Cells as Biomarkers for Bone Homeostasis in Osteoporosis |
581 400$
|
5 years |
| Sasha Bernatsky |
RI-MUHC |
Dose of Induction Methylprednisolone in Severe ANCA-Associated Vasculitis (DIMeS-AAV) |
86 875$ |
18 months |
| Yan Burelle |
Ottawa University |
Peroxisomes: A neglected metabolic organelle with a crucial role in the regulation of muscle stem cell regenerative properties |
753 526$ |
5 years |
| Michel Cayouette |
IRCM |
Light as a Morphogen: Unraveling a Novel Planar Cell Polarity Pathway in Retinal Function and Disease |
1 357 876$ |
5 years |
| Benoit Coulombe |
IRCM |
Neuroligin-1 and neuroligin-2 as blood biomarkers of prodromal Alzheimer’s disease |
879 750$ |
5 years |
| Nicolas Dupré |
CR-CHU Québec |
Étudier le rôle de la matrice extracellulaire dans la Sclérose Latérale Amyotrophique à l’aide de modèles in vitro 3D personnalisés produits par génie tissulaire |
1 017 450$ |
5 years |
| Wei-Hsiang Huang |
RI-MUHC |
Molecular pathogenesis of Smith-Magenis syndrome and developing therapy using hiPSC-derived neuronal models |
1 025 100$
|
5 years |
| Sarah Lippé |
CHU Sainte-Justine |
Multifeature Brain Investigation of Genetic Liability for Neurodevelopmental and Psychiatric Disorders |
772 650 $ |
5 years |
| Sarah Lippé |
CHU Sainte-Justine |
Assessing the Impact of Probiotic Supplementation in Children Diagnosed with Autism Spectrum Disorder: the PROBI-O-TISM Study |
608 176$ |
5 years |
| Gabrielle Pagé; Annie-Danielle Grenier; Catherine Côté; Anne-Marie Laberge |
CR-CHUM |
Vivre avec une maladie complexe, multisystémique et douloureuse : Cartographier le parcours de vie avec un trouble héréditaire du tissu conjonctif pour développer un parcours d’apprentissage patients |
397 800$ |
4 years |
| Kessen Patten; Guy A. Rouleau |
INRS
Neuro |
The role of C9orf72 in cerebellar function and movement disorders |
1 105 426$ |
4 years |
| Nicolas Pilon |
UQAM-CERMO-FC |
Preclinical development and safety evaluation of NEU-001: a potential one-fits-all drug for multiple gastrointestinal conditions |
1 101 600$ |
3 years |
